Ningbo Menovo Pharmaceutical News

Minovar (603538): Formulation processing business is starting to gain momentum and is optimistic that it will achieve restorative growth throughout the year

tianfeng securitiesNov 11, 2024 13:27

Minovar (603538): Cooperation with major customers continues to deepen, and API varieties are expected to unlock profits

tianfeng SecuritiesOct 23, 2024 19:21

Minova (603538): COVID-19 disturbances and rising production capacity affected short-term performance in Q3, starting to pick up

Oct 30, 2023 00:00

Minovar (603538): Strategic transformation is progressing smoothly under pressure from short-term performance

財通證券Sep 1, 2023 00:00

Minovar (603538): Costs, exchange rates, COVID-19 disturbances affect short-term performance formulations, and CDMO are expected to drive growth

中泰證券Aug 31, 2023 18:02

Minova (603538): The smooth promotion of the CDMO+ formulation business has led to a high increase in performance

財通證券Apr 6, 2023 00:00

Minova (603538): The specialty API business is steady, CDMO and pharmaceuticals are going hand in hand

財通證券Mar 18, 2023 00:00

Minova (603538): CDMO and pharmaceutical-driven rapid growth and sale of Liaoyuan further optimizes production capacity structure

中泰證券Oct 27, 2022 00:00

Minova (603538): CDMO and pharmaceuticals go hand in hand

長城國瑞證券Aug 18, 2022 00:00

Minova (603538) 2022 Interim Report Performance Review: Performance Meets Expectations and Stable Release of Production Capacity Supports Long-term Performance

東吳證券Aug 16, 2022 00:00

Minohua (603538): CDMO, preparations drive rapid growth strategy transformation and speed up

中泰證券Aug 15, 2022 00:00

Minohua (603538): CDMO business develops rapidly 2022H1 performance growth meets expectations

安信證券Jul 5, 2022 00:00

Minohua (603538): the rapid growth of CDMO and preparation business drives the company's performance to usher in an inflection point

信達證券May 16, 2022 19:21

Minohua (603538): accelerated upgrading and Transformation of CDMO Business 2022Q1 performance exceeds expectations

安信證券May 6, 2022 00:00

Minohua (603538): rapid growth of CDMO and preparation business in 2021 2022Q1 profit side doubles

興業證券Apr 28, 2022 00:00

Minova (603538) 2021 Report and 2022 Quarterly Report Reviews: Performance Meets Expectations, Formulation and CDMO Business Doubled Volume

東吳證券Apr 26, 2022 00:00

Minohua (603538): COVID-19 industry chain brings Q1 performance outbreak CDMO, preparation, API three-wheel drive

中泰證券Apr 25, 2022 00:00

Minovale (603538) in-depth report: capacity release accelerates layout of CDMO business

東莞證券Jan 10, 2022 13:17

Minohua (603538): the introduction of equity incentive has sufficient power for long-term development.

西南證券Nov 18, 2021 00:00

Minovale (603538): performance in line with expected preparations and increased share of CDMO business

西南證券Jul 29, 2021 00:00